MENU
+Compare
LIANY
Stock ticker: OTC
AS OF
Sep 23 closing price
Price
$0.06
Change
-$0.00 (-0.00%)
Capitalization
6.51M

LIANY stock forecast, quote, news & analysis

LianBio is a science-driven biopharmaceutical company dedicated to developing and commercializing medicines for patients with unmet medical needs, with an initial focus on in-licensing assets for Greater China and other Asian markets... Show more

LIANY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for LIANY with price predictions
Sep 23, 2025

LIANY in upward trend: price rose above 50-day moving average on September 23, 2025

LIANY moved above its 50-day moving average on September 23, 2025 date and that indicates a change from a downward trend to an upward trend. In of 28 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where LIANY's RSI Indicator exited the oversold zone, of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 46 cases where LIANY's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on September 17, 2025. You may want to consider a long position or call options on LIANY as a result. In of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The 10-day moving average for LIANY crossed bullishly above the 50-day moving average on September 23, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 10 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where LIANY advanced for three days, in of 160 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

LIANY broke above its upper Bollinger Band on September 23, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.032) is normal, around the industry mean (19.924). P/E Ratio (0.000) is within average values for comparable stocks, (54.318). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.126). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (347.892).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. LIANY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LIANY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
published Dividends

LIANY paid dividends on July 14, 2025

LianBio LIANY Stock Dividends
А quarterly dividend of $0.43 per share was paid with a record date of July 14, 2025, and an ex-dividend date of July 15, 2025. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Moderna (NASDAQ:MRNA), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 1.91B. The market cap for tickers in the group ranges from 31.65 to 97.36B. VRTX holds the highest valuation in this group at 97.36B. The lowest valued company is CYCCP at 31.65.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 5%. For the same Industry, the average monthly price growth was 11%, and the average quarterly price growth was 54%. SPRC experienced the highest price growth at 130%, while CURX experienced the biggest fall at -89%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -27%. For the same stocks of the Industry, the average monthly volume growth was -21% and the average quarterly volume growth was 93%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 82
Price Growth Rating: 56
SMR Rating: 93
Profit Risk Rating: 94
Seasonality Score: -21 (-100 ... +100)
View a ticker or compare two or three
LIANY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
103 Carnegie Center Drive
Phone
+1 609 486-2308
Employees
52
Web
https://www.lianbio.com